Daniel Lin

TitleAsst Professor
InstitutionThomas Jefferson University
DepartmentMedical Oncology
Address925 Chestnut Street
Philadelphia PA 19107
vCardDownload vCard

    Collapse Bibliographic 
    Collapse selected publications
    Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Faculty can login to make corrections and additions.
    Newest   |   Oldest   |   Most Cited   |   Most Discussed   |   Timeline   |   Field Summary   |   Plain Text
    PMC Citations indicate the number of times the publication was cited by articles in PubMed Central, and the Altmetric score represents citations in news articles and social media. (Note that publications are often cited in additional ways that are not shown here.) Fields are based on how the National Library of Medicine (NLM) classifies the publication's journal and might not represent the specific topic of the publication. Translation tags are based on the publication type and the MeSH terms NLM assigns to the publication. Some publications (especially newer ones and publications not in PubMed) might not yet be assigned Field or Translation tags.) Click a Field or Translation tag to filter the publications.
    1. Gaylis FD, Cooperberg MR, Chen RC, Malin J, Loeb S, Witte JS, Carroll PR, Cohen ES, Dato PE, Lin DW, Zheng Y, Seibert TM, Setzler C, Wilt W, Gomez SL, Chan JML, Catalona WJ. Defining Quality Metrics for Active Surveillance: The Michigan Urological Surgery Improvement Collaborative Experience. Letter. J Urol. 2021 Apr 05; 101097JU0000000000001781. PMID: 33818133.
      Citations:    
    2. Graham LS, True LD, Gulati R, Schade GR, Wright J, Grivas P, Yezefski T, Nega K, Alexander K, Hou WM, Yu EY, Montgomery B, Mostaghel EA, Matsumoto AA, Marck B, Sharifi N, Ellis WJ, Reder NP, Lin DW, Nelson PS, Schweizer MT. Targeting backdoor androgen synthesis through AKR1C3 inhibition: A presurgical hormonal ablative neoadjuvant trial in high-risk localized prostate cancer. Prostate. 2021 May; 81(7):418-426. PMID: 33755225.
      Citations:    
    3. Conti DV, Darst BF, Moss LC, Saunders EJ, Sheng X, Chou A, Schumacher FR, Olama AAA, Benlloch S, Dadaev T, Brook MN, Sahimi A, Hoffmann TJ, Takahashi A, Matsuda K, Momozawa Y, Fujita M, Muir K, Lophatananon A, Wan P, Le Marchand L, Wilkens LR, Stevens VL, Gapstur SM, Carter BD, Schleutker J, Tammela TLJ, Sipeky C, Auvinen A, Giles GG, Southey MC, MacInnis RJ, Cybulski C, Wokolorczyk D, Lubinski J, Neal DE, Donovan JL, Hamdy FC, Martin RM, Nordestgaard BG, Nielsen SF, Weischer M, Bojesen SE, Røder MA, Iversen P, Batra J, Chambers S, Moya L, Horvath L, Clements JA, Tilley W, Risbridger GP, Gronberg H, Aly M, Szulkin R, Eklund M, Nordström T, Pashayan N, Dunning AM, Ghoussaini M, Travis RC, Key TJ, Riboli E, Park JY, Sellers TA, Lin HY, Albanes D, Weinstein SJ, Mucci LA, Giovannucci E, Lindstrom S, Kraft P, Hunter DJ, Penney KL, Turman C, Tangen CM, Goodman PJ, Thompson IM, Hamilton RJ, Fleshner NE, Finelli A, Parent MÉ, Stanford JL, Ostrander EA, Geybels MS, Koutros S, Freeman LEB, Stampfer M, Wolk A, Håkansson N, Andriole GL, Hoover RN, Machiela MJ, Sørensen KD, Borre M, Blot WJ, Zheng W, Yeboah ED, Mensah JE, Lu YJ, Zhang HW, Feng N, Mao X, Wu Y, Zhao SC, Sun Z, Thibodeau SN, McDonnell SK, Schaid DJ, West CML, Burnet N, Barnett G, Maier C, Schnoeller T, Luedeke M, Kibel AS, Drake BF, Cussenot O, Cancel-Tassin G, Menegaux F, Truong T, Koudou YA, John EM, Grindedal EM, Maehle L, Khaw KT, Ingles SA, Stern MC, Vega A, Gómez-Caamaño A, Fachal L, Rosenstein BS, Kerns SL, Ostrer H, Teixeira MR, Paulo P, Brandão A, Watya S, Lubwama A, Bensen JT, Fontham ETH, Mohler J, Taylor JA, Kogevinas M, Llorca J, Castaño-Vinyals G, Cannon-Albright L, Teerlink CC, Huff CD, Strom SS, Multigner L, Blanchet P, Brureau L, Kaneva R, Slavov C, Mitev V, Leach RJ, Weaver B, Brenner H, Cuk K, Holleczek B, Saum KU, Klein EA, Hsing AW, Kittles RA, Murphy AB, Logothetis CJ, Kim J, Neuhausen SL, Steele L, Ding YC, Isaacs WB, Nemesure B, Hennis AJM, Carpten J, Pandha H, Michael A, De Ruyck K, De Meerleer G, Ost P, Xu J, Razack A, Lim J, Teo SH, Newcomb LF, Lin DW, Fowke JH, Neslund-Dudas C, Rybicki BA, Gamulin M, Lessel D, Kulis T, Usmani N, Singhal S, Parliament M, Claessens F, Joniau S, Van den Broeck T, Gago-Dominguez M, Castelao JE, Martinez ME, Larkin S, Townsend PA, Aukim-Hastie C, Bush WS, Aldrich MC, Crawford DC, Srivastava S, Cullen JC, Petrovics G, Casey G, Roobol MJ, Jenster G, van Schaik RHN, Hu JJ, Sanderson M, Varma R, McKean-Cowdin R, Torres M, Mancuso N, Berndt SI, Van Den Eeden SK, Easton DF, Chanock SJ, Cook MB, Wiklund F, Nakagawa H, Witte JS, Eeles RA, Kote-Jarai Z, Haiman CA. Publisher Correction: Trans-ancestry genome-wide association meta-analysis of prostate cancer identifies new susceptibility loci and informs genetic risk prediction. Nat Genet. 2021 Mar; 53(3):413. PMID: 33473200.
      Citations:    
    4. Diamantopoulos LN, Sekar RR, Holt SK, Khaki AR, Miller NJ, Gadzinski A, Nyame YA, Vakar-Lopez F, Tretiakova MS, Psutka SP, Gore JL, Lin DW, Schade GR, Hsieh AC, Lee JK, Yezefski T, Schweizer MT, Cheng HH, Yu EY, True LD, Montgomery RB, Grivas P, Wright JL. Patterns and timing of perioperative blood transfusion and association with outcomes after radical cystectomy. Urol Oncol. 2021 Feb 04. PMID: 33551249.
      Citations:    
    5. Labrecque MP, Brown LG, Coleman IM, Nguyen HM, Lin DW, Corey E, Nelson PS, Morrissey C. Cabozantinib can block growth of neuroendocrine prostate cancer patient-derived xenografts by disrupting tumor vasculature. PLoS One. 2021; 16(1):e0245602. PMID: 33471819.
      Citations:    
    6. Conti DV, Darst BF, Moss LC, Saunders EJ, Sheng X, Chou A, Schumacher FR, Olama AAA, Benlloch S, Dadaev T, Brook MN, Sahimi A, Hoffmann TJ, Takahashi A, Matsuda K, Momozawa Y, Fujita M, Muir K, Lophatananon A, Wan P, Le Marchand L, Wilkens LR, Stevens VL, Gapstur SM, Carter BD, Schleutker J, Tammela TLJ, Sipeky C, Auvinen A, Giles GG, Southey MC, MacInnis RJ, Cybulski C, Wokolorczyk D, Lubinski J, Neal DE, Donovan JL, Hamdy FC, Martin RM, Nordestgaard BG, Nielsen SF, Weischer M, Bojesen SE, Røder MA, Iversen P, Batra J, Chambers S, Moya L, Horvath L, Clements JA, Tilley W, Risbridger GP, Gronberg H, Aly M, Szulkin R, Eklund M, Nordström T, Pashayan N, Dunning AM, Ghoussaini M, Travis RC, Key TJ, Riboli E, Park JY, Sellers TA, Lin HY, Albanes D, Weinstein SJ, Mucci LA, Giovannucci E, Lindstrom S, Kraft P, Hunter DJ, Penney KL, Turman C, Tangen CM, Goodman PJ, Thompson IM, Hamilton RJ, Fleshner NE, Finelli A, Parent MÉ, Stanford JL, Ostrander EA, Geybels MS, Koutros S, Freeman LEB, Stampfer M, Wolk A, Håkansson N, Andriole GL, Hoover RN, Machiela MJ, Sørensen KD, Borre M, Blot WJ, Zheng W, Yeboah ED, Mensah JE, Lu YJ, Zhang HW, Feng N, Mao X, Wu Y, Zhao SC, Sun Z, Thibodeau SN, McDonnell SK, Schaid DJ, West CML, Burnet N, Barnett G, Maier C, Schnoeller T, Luedeke M, Kibel AS, Drake BF, Cussenot O, Cancel-Tassin G, Menegaux F, Truong T, Koudou YA, John EM, Grindedal EM, Maehle L, Khaw KT, Ingles SA, Stern MC, Vega A, Gómez-Caamaño A, Fachal L, Rosenstein BS, Kerns SL, Ostrer H, Teixeira MR, Paulo P, Brandão A, Watya S, Lubwama A, Bensen JT, Fontham ETH, Mohler J, Taylor JA, Kogevinas M, Llorca J, Castaño-Vinyals G, Cannon-Albright L, Teerlink CC, Huff CD, Strom SS, Multigner L, Blanchet P, Brureau L, Kaneva R, Slavov C, Mitev V, Leach RJ, Weaver B, Brenner H, Cuk K, Holleczek B, Saum KU, Klein EA, Hsing AW, Kittles RA, Murphy AB, Logothetis CJ, Kim J, Neuhausen SL, Steele L, Ding YC, Isaacs WB, Nemesure B, Hennis AJM, Carpten J, Pandha H, Michael A, De Ruyck K, De Meerleer G, Ost P, Xu J, Razack A, Lim J, Teo SH, Newcomb LF, Lin DW, Fowke JH, Neslund-Dudas C, Rybicki BA, Gamulin M, Lessel D, Kulis T, Usmani N, Singhal S, Parliament M, Claessens F, Joniau S, Van den Broeck T, Gago-Dominguez M, Castelao JE, Martinez ME, Larkin S, Townsend PA, Aukim-Hastie C, Bush WS, Aldrich MC, Crawford DC, Srivastava S, Cullen JC, Petrovics G, Casey G, Roobol MJ, Jenster G, van Schaik RHN, Hu JJ, Sanderson M, Varma R, McKean-Cowdin R, Torres M, Mancuso N, Berndt SI, Van Den Eeden SK, Easton DF, Chanock SJ, Cook MB, Wiklund F, Nakagawa H, Witte JS, Eeles RA, Kote-Jarai Z, Haiman CA. Trans-ancestry genome-wide association meta-analysis of prostate cancer identifies new susceptibility loci and informs genetic risk prediction. Nat Genet. 2021 Jan; 53(1):65-75. PMID: 33398198.
      Citations:    
    7. Nyame YA, Holt SK, Diamontopoulos LN, Winters BR, Psutka SP, Dash A, Schade GR, Lin DW, Yu EY, Grivas P, Gore JL, Wright JL. Social and Clinical Correlates of Neoadjuvant Chemotherapy in Medicare Beneficiaries With Muscle Invasive Bladder Cancer From 2004-2015. Urology. 2020 Dec 26. PMID: 33373709.
      Citations:    
    8. Cooperberg MR, Cowan JE, Lindquist KJ, Kobayashi Y, Simko JP, Bengtsson H, Singh K, Ngo V, Avila A, Newcomb LF, Tretriakova M, Lin DW, Stone S, Carroll PR, Paris PL. Multiple Tissue Biomarkers Independently and Additively Predict Prostate Cancer Pathology Outcomes. Eur Urol. 2021 Jan; 79(1):141-149. PMID: 33148472.
      Citations:    
    9. Diamantopoulos LN, Holt SK, Khaki AR, Sekar RR, Gadzinski A, Nyame YA, Vakar-Lopez F, Tretiakova MS, Psutka SP, Gore JL, Lin DW, Schade GR, Hsieh AC, Lee JK, Yezefski T, Schweizer MT, Cheng HH, Yu EY, True LD, Montgomery RB, Grivas P, Wright JL. Response to Neoadjuvant Chemotherapy and Survival in Micropapillary Urothelial Carcinoma: Data From a Tertiary Referral Center and the Surveillance, Epidemiology, and End Results (SEER) Program. Clin Genitourin Cancer. 2020 Oct 14. PMID: 33160889.
      Citations:    
    10. Cooperberg MR, Zheng Y, Faino AV, Newcomb LF, Zhu K, Cowan JE, Brooks JD, Dash A, Gleave ME, Martin F, Morgan TM, Nelson PS, Thompson IM, Wagner AA, Carroll PR, Lin DW. Tailoring Intensity of Active Surveillance for Low-Risk Prostate Cancer Based on Individualized Prediction of Risk Stability. JAMA Oncol. 2020 Aug 27; e203187. PMID: 32852532.
      Citations:    
    11. Shore ND, Drake CG, Lin DW, Ryan CJ, Stratton KL, Dunshee C, Karsh LI, Kaul S, Kernen K, Pieczonka C, Sieber P, Stewart C, Williams M, Concepcion RS. Optimizing the management of castration-resistant prostate cancer patients: A practical guide for clinicians. Prostate. 2020 Aug 11. PMID: 32779781.
      Citations:    
    12. Giri VN, Knudsen KE, Kelly WK, Cheng HH, Cooney KA, Cookson MS, Dahut W, Weissman S, Soule HR, Petrylak DP, Dicker AP, AlDubayan SH, Toland AE, Pritchard CC, Pettaway CA, Daly MB, Mohler JL, Parsons JK, Carroll PR, Pilarski R, Blanco A, Woodson A, Rahm A, Taplin ME, Polascik TJ, Helfand BT, Hyatt C, Morgans AK, Feng F, Mullane M, Powers J, Concepcion R, Lin DW, Wender R, Mark JR, Costello A, Burnett AL, Sartor O, Isaacs WB, Xu J, Weitzel J, Andriole GL, Beltran H, Briganti A, Byrne L, Calvaresi A, Chandrasekar T, Chen DYT, Den RB, Dobi A, Crawford ED, Eastham J, Eggener S, Freedman ML, Garnick M, Gomella PT, Handley N, Hurwitz MD, Izes J, Karnes RJ, Lallas C, Languino L, Loeb S, Lopez AM, Loughlin KR, Lu-Yao G, Malkowicz SB, Mann M, Mille P, Miner MM, Morgan T, Moreno J, Mucci L, Myers RE, Nielsen SM, O'Neil B, Pinover W, Pinto P, Poage W, Raj GV, Rebbeck TR, Ryan C, Sandler H, Schiewer M, Scott EMD, Szymaniak B, Tester W, Trabulsi EJ, Vapiwala N, Yu EY, Zeigler-Johnson C, Gomella LG. Implementation of Germline Testing for Prostate Cancer: Philadelphia Prostate Cancer Consensus Conference 2019. J Clin Oncol. 2020 Jun 09; JCO2000046. PMID: 32516092.
      Citations:    
    13. Liss MA, Newcomb LF, Zheng Y, Garcia MP, Filson CP, Boyer H, Brooks JD, Carroll PR, Cooperberg MR, Ellis WJ, Gleave ME, Martin FM, Morgan T, Nelson PS, Wagner AA, Thompson IM, Lin DW. Magnetic Resonance Imaging for the Detection of High-Grade Cancer in the Canary Prostate Active Surveillance Study. J Urol. 2020 Apr 28; 101097JU0000000000001088. PMID: 32343189.
      Citations:    
    14. Cooperberg MR, Lin DW. Active Surveillance for Prostate Cancer: A 2020 Vision. Eur Urol. 2020 Apr 10. PMID: 32284244.
      Citations:    
    15. Madan RA, Antonarakis ES, Drake CG, Fong L, Yu EY, McNeel DG, Lin DW, Chang NN, Sheikh NA, Gulley JL. Putting the Pieces Together: Completing the Mechanism of Action Jigsaw for Sipuleucel-T. J Natl Cancer Inst. 2020 Mar 07. PMID: 32145020.
      Citations:    
    16. Lin DW, Zheng Y, McKenney JK, Brown MD, Lu R, Crager M, Boyer H, Tretiakova M, Brooks JD, Dash A, Fabrizio MD, Gleave ME, Kolb S, Liss M, Morgan TM, Thompson IM, Wagner AA, Tsiatis A, Pingitore A, Nelson PS, Newcomb LF. 17-Gene Genomic Prostate Score Test Results in the Canary Prostate Active Surveillance Study (PASS) Cohort. J Clin Oncol. 2020 Mar 04; JCO1902267. PMID: 32130059.
      Citations:    
    17. Schenk JM, Newcomb LF, Zheng Y, Faino AV, Zhu K, Nyame YA, Brooks JD, Carroll PR, Cooperberg MR, Dash A, Filson CP, Gleave ME, Liss M, Martin FM, Morgan TM, Nelson PS, Thompson IM, Wagner AA, Lin DW. Reply by Authors. J Urol. 2020 Jan 17; 101097JU000000000000062102. PMID: 31951502.
      Citations:    
    18. Lin DW, Shih MC, Aronson W, Basler J, Beer TM, Brophy M, Cooperberg M, Garzotto M, Kelly WK, Lee K, McGuire V, Wang Y, Lu Y, Markle V, Nseyo U, Ringer R, Savage SJ, Sinnott P, Uchio E, Yang CC, Montgomery RB. Veterans Affairs Cooperative Studies Program Study #553: Chemotherapy After Prostatectomy for High-risk Prostate Carcinoma: A Phase III Randomized Study. Eur Urol. 2020 Jan 07. PMID: 31924316.
      Citations:    
    19. Gilligan T, Lin DW, Aggarwal R, Chism D, Cost N, Derweesh IH, Emamekhoo H, Feldman DR, Geynisman DM, Hancock SL, LaGrange C, Levine EG, Longo T, Lowrance W, McGregor B, Monk P, Picus J, Pierorazio P, Rais-Bahrami S, Saylor P, Sircar K, Smith DC, Tzou K, Vaena D, Vaughn D, Yamoah K, Yamzon J, Johnson-Chilla A, Keller J, Pluchino LA. Testicular Cancer, Version 2.2020, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw. 2019 Dec; 17(12):1529-1554. PMID: 31805523.
      Citations:    
    20. Gore JL, du Plessis M, Zhang J, Dai D, Thompson DJS, Karsh L, Lane B, Franks M, Chen DYT, Bianco FJ, Brown G, Clark W, Kibel AS, Kim H, Lowrance W, Manoharan M, Maroni P, Perrapato S, Sieber P, Trabulsi EJ, Waterhouse R, Spratt DE, Davicioni E, Lotan Y, Lin DW. Clinical Utility of a Genomic Classifier in Men Undergoing Radical Prostatectomy: The PRO-IMPACT Trial. Pract Radiat Oncol. 2019 Nov 20. PMID: 31761540.
      Citations:    
    21. Marascio J, Spratt DE, Zhang J, Trabulsi EJ, Le T, Sedzorme WS, Beeler WH, Davicioni E, Dabbas B, Lin DW, Gore JL, Bloom M, Mann M, Mark JR, Calvaresi A, Godwin JL, McCue P, Hurwitz MD, Kelly WK, Lallas CD, Knudsen KE, Gomella LG, Dicker AP, Den RB. Prospective study to define the clinical utility and benefit of Decipher testing in men following prostatectomy. Prostate Cancer Prostatic Dis. 2019 Nov 12. PMID: 31719663.
      Citations:    
    22. Schenk JM, Newcomb LF, Zheng Y, Faino AV, Zhu K, Nyame YA, Brooks JD, Carroll PR, Cooperberg MR, Dash A, Filson CP, Gleave ME, Liss M, Martin FM, Morgan TM, Nelson PS, Thompson IM, Wagner AA, Lin DW. African American Race is Not Associated with Risk of Reclassification during Active Surveillance: Results from the Canary Prostate Cancer Active Surveillance Study (PASS). J Urol. 2019 Oct 25; 101097JU0000000000000621. PMID: 31651227.
      Citations:    
    23. Lange JM, Laviana AA, Penson DF, Lin DW, Bill-Axelson A, Carlsson SV, Newcomb LF, Trock BJ, Carter HB, Carroll PR, Cooperberg MR, Cowan JE, Klotz LH, Etzioni RB. Prostate cancer mortality and metastasis under different biopsy frequencies in North American active surveillance cohorts. Cancer. 2019 Oct 22. PMID: 31639200.
      Citations:    
    24. Lam TBL, MacLennan S, Willemse PM, Mason MD, Plass K, Shepherd R, Baanders R, Bangma CH, Bjartell A, Bossi A, Briers E, Briganti A, Buddingh KT, Catto JWF, Colecchia M, Cox BW, Cumberbatch MG, Davies J, Davis NF, De Santis M, Dell'Oglio P, Deschamps A, Donaldson JF, Egawa S, Fankhauser CD, Fanti S, Fossati N, Gandaglia G, Gillessen S, Grivas N, Gross T, Grummet JP, Henry AM, Ingels A, Irani J, Lardas M, Liew M, Lin DW, Moris L, Omar MI, Pang KH, Paterson CC, Renard-Penna R, Ribal MJ, Roobol MJ, Rouprêt M, Rouvière O, Sancho Pardo G, Richenberg J, Schoots IG, Sedelaar JPM, Stricker P, Tilki D, Vahr Lauridsen S, van den Bergh RCN, Van den Broeck T, van der Kwast TH, van der Poel HG, van Leenders GJLH, Varma M, Violette PD, Wallis CJD, Wiegel T, Wilkinson K, Zattoni F, N'Dow JMO, Van Poppel H, Cornford P, Mottet N. EAU-EANM-ESTRO-ESUR-SIOG Prostate Cancer Guideline Panel Consensus Statements for Deferred Treatment with Curative Intent for Localised Prostate Cancer from an International Collaborative Study (DETECTIVE Study). Eur Urol. 2019 Oct 03. PMID: 31587989.
      Citations:    
    25. Nayak JG, Scalzo N, Chu A, Shiff B, Kearns JT, Dy GW, Macleod LC, Mossanen M, Ellis WJ, Lin DW, Wright JL, True LD, Gore JL. The development and comparative effectiveness of a patient-centered prostate biopsy report: a prospective, randomized study. Prostate Cancer Prostatic Dis. 2019 Aug 28. PMID: 31462701.
      Citations:    
    26. Labrecque MP, Coleman IM, Brown LG, True LD, Kollath L, Lakely B, Nguyen HM, Yang YC, da Costa RMG, Kaipainen A, Coleman R, Higano CS, Yu EY, Cheng HH, Mostaghel EA, Montgomery B, Schweizer MT, Hsieh AC, Lin DW, Corey E, Nelson PS, Morrissey C. Molecular profiling stratifies diverse phenotypes of treatment-refractory metastatic castration-resistant prostate cancer. J Clin Invest. 2019 07 30; 129(10):4492-4505. PMID: 31361600.
      Citations:    
    27. Cooperberg MR, Carroll PR, Dall'Era MA, Davies BJ, Davis JW, Eggener SE, Feng FY, Lin DW, Morgan TM, Morgans AK, Spratt DE, Taneja SS, Penson DF. The State of the Science on Prostate Cancer Biomarkers: The San Francisco Consensus Statement. Eur Urol. 2019 Sep; 76(3):268-272. PMID: 31128968.
      Citations:    
    28. Lin D, Khan U, Goetze TO, Reizine N, Goodman KA, Shah MA, Catenacci DV, Al-Batran SE, Posey JA. Gastroesophageal Junction Adenocarcinoma: Is There an Optimal Management? Am Soc Clin Oncol Educ Book. 2019 Jan; 39:e88-e95. PMID: 31099690.
      Citations:    
    29. Schenk JM, Neuhouser ML, Beatty SJ, VanDoren M, Lin DW, Porter M, Gore JL, Gulati R, Plymate SR, Wright JL. Randomized trial evaluating the role of weight loss in overweight and obese men with early stage prostate Cancer on active surveillance: Rationale and design of the Prostate Cancer Active Lifestyle Study (PALS). Contemp Clin Trials. 2019 Jun; 81:34-39. PMID: 31002955.
      Citations:    
    30. McKay RR, Ye H, Xie W, Lis R, Calagua C, Zhang Z, Trinh QD, Chang SL, Harshman LC, Ross AE, Pienta KJ, Lin DW, Ellis WJ, Montgomery B, Chang P, Wagner AA, Bubley GJ, Kibel AS, Taplin ME. Evaluation of Intense Androgen Deprivation Before Prostatectomy: A Randomized Phase II Trial of Enzalutamide and Leuprolide With or Without Abiraterone. J Clin Oncol. 2019 Feb 27; JCO1801777. PMID: 30811282.
      Citations:    
    31. Schumacher FR, Olama AAA, Berndt SI, Benlloch S, Ahmed M, Saunders EJ, Dadaev T, Leongamornlert D, Anokian E, Cieza-Borrella C, Goh C, Brook MN, Sheng X, Fachal L, Dennis J, Tyrer J, Muir K, Lophatananon A, Stevens VL, Gapstur SM, Carter BD, Tangen CM, Goodman PJ, Thompson IM, Batra J, Chambers S, Moya L, Clements J, Horvath L, Tilley W, Risbridger GP, Gronberg H, Aly M, Nordström T, Pharoah P, Pashayan N, Schleutker J, Tammela TLJ, Sipeky C, Auvinen A, Albanes D, Weinstein S, Wolk A, Håkansson N, West CML, Dunning AM, Burnet N, Mucci LA, Giovannucci E, Andriole GL, Cussenot O, Cancel-Tassin G, Koutros S, Beane Freeman LE, Sorensen KD, Orntoft TF, Borre M, Maehle L, Grindedal EM, Neal DE, Donovan JL, Hamdy FC, Martin RM, Travis RC, Key TJ, Hamilton RJ, Fleshner NE, Finelli A, Ingles SA, Stern MC, Rosenstein BS, Kerns SL, Ostrer H, Lu YJ, Zhang HW, Feng N, Mao X, Guo X, Wang G, Sun Z, Giles GG, Southey MC, MacInnis RJ, FitzGerald LM, Kibel AS, Drake BF, Vega A, Gómez-Caamaño A, Szulkin R, Eklund M, Kogevinas M, Llorca J, Castaño-Vinyals G, Penney KL, Stampfer M, Park JY, Sellers TA, Lin HY, Stanford JL, Cybulski C, Wokolorczyk D, Lubinski J, Ostrander EA, Geybels MS, Nordestgaard BG, Nielsen SF, Weischer M, Bisbjerg R, Røder MA, Iversen P, Brenner H, Cuk K, Holleczek B, Maier C, Luedeke M, Schnoeller T, Kim J, Logothetis CJ, John EM, Teixeira MR, Paulo P, Cardoso M, Neuhausen SL, Steele L, Ding YC, De Ruyck K, De Meerleer G, Ost P, Razack A, Lim J, Teo SH, Lin DW, Newcomb LF, Lessel D, Gamulin M, Kulis T, Kaneva R, Usmani N, Singhal S, Slavov C, Mitev V, Parliament M, Claessens F, Joniau S, Van den Broeck T, Larkin S, Townsend PA, Aukim-Hastie C, Gago-Dominguez M, Castelao JE, Martinez ME, Roobol MJ, Jenster G, van Schaik RHN, Menegaux F, Truong T, Koudou YA, Xu J, Khaw KT, Cannon-Albright L, Pandha H, Michael A, Thibodeau SN, McDonnell SK, Schaid DJ, Lindstrom S, Turman C, Ma J, Hunter DJ, Riboli E, Siddiq A, Canzian F, Kolonel LN, Le Marchand L, Hoover RN, Machiela MJ, Cui Z, Kraft P, Amos CI, Conti DV, Easton DF, Wiklund F, Chanock SJ, Henderson BE, Kote-Jarai Z, Haiman CA, Eeles RA. Author Correction: Association analyses of more than 140,000 men identify 63 new prostate cancer susceptibility loci. Nat Genet. 2019 Feb; 51(2):363. PMID: 30622367.
      Citations:    
    32. Newcomb LF, Zheng Y, Faino AV, Bianchi-Frias D, Cooperberg MR, Brown MD, Brooks JD, Dash A, Fabrizio MD, Gleave ME, Liss M, Morgan TM, Thompson IM, Wagner AA, Carroll PR, Nelson PS, Lin DW. Performance of PCA3 and TMPRSS2:ERG urinary biomarkers in prediction of biopsy outcome in the Canary Prostate Active Surveillance Study (PASS). Prostate Cancer Prostatic Dis. 2019 Jan 21. PMID: 30664734.
      Citations:    
    33. Kearns JT, Winters BD, Holt SK, Mossanen M, Lin DW, Wright JL. Pathologic Nodal Involvement in Patients With Penile Cancer With Cavernosal Versus Spongiosal Involvement. Clin Genitourin Cancer. 2019 Feb; 17(1):e156-e161. PMID: 30448105.
      Citations:    
    34. Lange JM, Gulati R, Leonardson AS, Lin DW, Newcomb LF, Trock BJ, Carter HB, Cooperberg MR, Cowan JE, Klotz LH, Etzioni R. ESTIMATING AND COMPARING CANCER PROGRESSION RISKS UNDER VARYING SURVEILLANCE PROTOCOLS. Ann Appl Stat. 2018 Sep; 12(3):1773-1795. PMID: 30627300.
      Citations:    
    35. Kearns JT, Newcomb LF, Lin DW. Reply to Runqiang Yuan's Letter to the Editor re: James T. Kearns, Anna V. Faino, Lisa F. Newcomb, et al. Role of Surveillance Biopsy with No Cancer as a Prognostic Marker for Reclassification: Results from the Canary Prostate Active Surveillance Study. Eur Urol 2018;73:706-12. Eur Urol. 2018 Sep 05. PMID: 30195835.
      Citations:    
    36. Kearns JT, Lin DW. Improving the Specificity of PSA Screening with Serum and Urine Markers. Curr Urol Rep. 2018 Aug 13; 19(10):80. PMID: 30105509.
      Citations:    
    37. Kearns JT, Faino AV, Schenk JM, Newcomb LF, Brooks JD, Carroll PR, Dash A, Ellis WJ, Fabrizio M, Gleave ME, Morgan TM, Nelson PS, Thompson IM, Wagner A, Zheng Y, Lin DW. Continued Five-Alpha Reductase Inhibitor Use After Prostate Cancer Diagnosis and the Risk of Reclassification and Adverse Pathological Outcomes in the Canary Prostate Active Surveillance Study (PASS). J Urol. 2018 Aug 01. PMID: 30076904.
      Citations:    
    38. Schumacher FR, Al Olama AA, Berndt SI, Benlloch S, Ahmed M, Saunders EJ, Dadaev T, Leongamornlert D, Anokian E, Cieza-Borrella C, Goh C, Brook MN, Sheng X, Fachal L, Dennis J, Tyrer J, Muir K, Lophatananon A, Stevens VL, Gapstur SM, Carter BD, Tangen CM, Goodman PJ, Thompson IM, Batra J, Chambers S, Moya L, Clements J, Horvath L, Tilley W, Risbridger GP, Gronberg H, Aly M, Nordström T, Pharoah P, Pashayan N, Schleutker J, Tammela TLJ, Sipeky C, Auvinen A, Albanes D, Weinstein S, Wolk A, Håkansson N, West CML, Dunning AM, Burnet N, Mucci LA, Giovannucci E, Andriole GL, Cussenot O, Cancel-Tassin G, Koutros S, Beane Freeman LE, Sorensen KD, Orntoft TF, Borre M, Maehle L, Grindedal EM, Neal DE, Donovan JL, Hamdy FC, Martin RM, Travis RC, Key TJ, Hamilton RJ, Fleshner NE, Finelli A, Ingles SA, Stern MC, Rosenstein BS, Kerns SL, Ostrer H, Lu YJ, Zhang HW, Feng N, Mao X, Guo X, Wang G, Sun Z, Giles GG, Southey MC, MacInnis RJ, FitzGerald LM, Kibel AS, Drake BF, Vega A, Gómez-Caamaño A, Szulkin R, Eklund M, Kogevinas M, Llorca J, Castaño-Vinyals G, Penney KL, Stampfer M, Park JY, Sellers TA, Lin HY, Stanford JL, Cybulski C, Wokolorczyk D, Lubinski J, Ostrander EA, Geybels MS, Nordestgaard BG, Nielsen SF, Weischer M, Bisbjerg R, Røder MA, Iversen P, Brenner H, Cuk K, Holleczek B, Maier C, Luedeke M, Schnoeller T, Kim J, Logothetis CJ, John EM, Teixeira MR, Paulo P, Cardoso M, Neuhausen SL, Steele L, Ding YC, De Ruyck K, De Meerleer G, Ost P, Razack A, Lim J, Teo SH, Lin DW, Newcomb LF, Lessel D, Gamulin M, Kulis T, Kaneva R, Usmani N, Singhal S, Slavov C, Mitev V, Parliament M, Claessens F, Joniau S, Van den Broeck T, Larkin S, Townsend PA, Aukim-Hastie C, Dominguez MG, Castelao JE, Martinez ME, Roobol MJ, Jenster G, van Schaik RHN, Menegaux F, Truong T, Koudou YA, Xu J, Khaw KT, Cannon-Albright L, Pandha H, Michael A, Thibodeau SN, McDonnell SK, Schaid DJ, Lindstrom S, Turman C, Ma J, Hunter DJ, Riboli E, Siddiq A, Canzian F, Kolonel LN, Le Marchand L, Hoover RN, Machiela MJ, Cui Z, Kraft P, Amos CI, Conti DV, Easton DF, Wiklund F, Chanock SJ, Henderson BE, Kote-Jarai Z, Haiman CA, Eeles RA. Association analyses of more than 140,000 men identify 63 new prostate cancer susceptibility loci. Nat Genet. 2018 Jun 11. PMID: 29892016.
      Citations:    
    39. Dadaev T, Saunders EJ, Newcombe PJ, Anokian E, Leongamornlert DA, Brook MN, Cieza-Borrella C, Mijuskovic M, Wakerell S, Olama AAA, Schumacher FR, Berndt SI, Benlloch S, Ahmed M, Goh C, Sheng X, Zhang Z, Muir K, Govindasami K, Lophatananon A, Stevens VL, Gapstur SM, Carter BD, Tangen CM, Goodman P, Thompson IM, Batra J, Chambers S, Moya L, Clements J, Horvath L, Tilley W, Risbridger G, Gronberg H, Aly M, Nordström T, Pharoah P, Pashayan N, Schleutker J, Tammela TLJ, Sipeky C, Auvinen A, Albanes D, Weinstein S, Wolk A, Hakansson N, West C, Dunning AM, Burnet N, Mucci L, Giovannucci E, Andriole G, Cussenot O, Cancel-Tassin G, Koutros S, Freeman LEB, Sorensen KD, Orntoft TF, Borre M, Maehle L, Grindedal EM, Neal DE, Donovan JL, Hamdy FC, Martin RM, Travis RC, Key TJ, Hamilton RJ, Fleshner NE, Finelli A, Ingles SA, Stern MC, Rosenstein B, Kerns S, Ostrer H, Lu YJ, Zhang HW, Feng N, Mao X, Guo X, Wang G, Sun Z, Giles GG, Southey MC, MacInnis RJ, FitzGerald LM, Kibel AS, Drake BF, Vega A, Gómez-Caamaño A, Fachal L, Szulkin R, Eklund M, Kogevinas M, Llorca J, Castaño-Vinyals G, Penney KL, Stampfer M, Park JY, Sellers TA, Lin HY, Stanford JL, Cybulski C, Wokolorczyk D, Lubinski J, Ostrander EA, Geybels MS, Nordestgaard BG, Nielsen SF, Weisher M, Bisbjerg R, Røder MA, Iversen P, Brenner H, Cuk K, Holleczek B, Maier C, Luedeke M, Schnoeller T, Kim J, Logothetis CJ, John EM, Teixeira MR, Paulo P, Cardoso M, Neuhausen SL, Steele L, Ding YC, De Ruyck K, De Meerleer G, Ost P, Razack A, Lim J, Teo SH, Lin DW, Newcomb LF, Lessel D, Gamulin M, Kulis T, Kaneva R, Usmani N, Slavov C, Mitev V, Parliament M, Singhal S, Claessens F, Joniau S, Van den Broeck T, Larkin S, Townsend PA, Aukim-Hastie C, Gago-Dominguez M, Castelao JE, Martinez ME, Roobol MJ, Jenster G, van Schaik RHN, Menegaux F, Truong T, Koudou YA, Xu J, Khaw KT, Cannon-Albright L, Pandha H, Michael A, Kierzek A, Thibodeau SN, McDonnell SK, Schaid DJ, Lindstrom S, Turman C, Ma J, Hunter DJ, Riboli E, Siddiq A, Canzian F, Kolonel LN, Le Marchand L, Hoover RN, Machiela MJ, Kraft P, Freedman M, Wiklund F, Chanock S, Henderson BE, Easton DF, Haiman CA, Eeles RA, Conti DV, Kote-Jarai Z. Fine-mapping of prostate cancer susceptibility loci in a large meta-analysis identifies candidate causal variants. Nat Commun. 2018 Jun 11; 9(1):2256. PMID: 29892050.
      Citations:    
    40. Kearns JT, Holt SK, Wright JL, Lin DW, Lange PH, Gore JL. PSA screening, prostate biopsy, and treatment of prostate cancer in the years surrounding the USPSTF recommendation against prostate cancer screening. Cancer. 2018 07 01; 124(13):2733-2739. PMID: 29781117.
      Citations:    
    41. Lin DW, Crawford ED, Keane T, Evans B, Reid J, Rajamani S, Brown K, Gutin A, Tward J, Scardino P, Brawer M, Stone S, Cuzick J. Identification of men with low-risk biopsy-confirmed prostate cancer as candidates for active surveillance. Urol Oncol. 2018 Apr 11. PMID: 29655620.
      Citations:    
    42. Hussain M, Tangen CM, Thompson IM, Swanson GP, Wood DP, Sakr W, Dawson NA, Haas NB, Flaig TW, Dorff TB, Lin DW, Crawford ED, Quinn DI, Vogelzang NJ, Glode LM. Phase III Intergroup Trial of Adjuvant Androgen Deprivation With or Without Mitoxantrone Plus Prednisone in Patients With High-Risk Prostate Cancer After Radical Prostatectomy: SWOG S9921. J Clin Oncol. 2018 May 20; 36(15):1498-1504. PMID: 29624463.
      Citations:    
    43. Montgomery B, Lin DW. Adjuvant Chemotherapy for Prostate Cancer: The Long and Winding Road. Eur Urol. 2018 Mar 08. PMID: 29526500.
      Citations:    
    44. Macleod LC, Cannon SS, Ko O, Schade GR, Wright JL, Lin DW, Holt SK, Gore JL, Dash A. Disparities in Access and Regionalization of Care in Testicular Cancer. Clin Genitourin Cancer. 2018 Feb 23. PMID: 29605587.
      Citations:    
    45. Cooperberg MR, Brooks JD, Faino AV, Newcomb LF, Kearns JT, Carroll PR, Dash A, Etzioni R, Fabrizio MD, Gleave ME, Morgan TM, Nelson PS, Thompson IM, Wagner AA, Lin DW, Zheng Y. Refined Analysis of Prostate-specific Antigen Kinetics to Predict Prostate Cancer Active Surveillance Outcomes. Eur Urol. 2018 Feb 09. PMID: 29433975.
      Citations:    
    46. Kearns JT, Faino AV, Newcomb LF, Brooks JD, Carroll PR, Dash A, Ellis WJ, Fabrizio M, Gleave ME, Morgan TM, Nelson PS, Thompson IM, Wagner AA, Zheng Y, Lin DW. Role of Surveillance Biopsy with No Cancer as a Prognostic Marker for Reclassification: Results from the Canary Prostate Active Surveillance Study. Eur Urol. 2018 Feb 09. PMID: 29433973.
      Citations:    
    47. Flanders SC, Kim J, Wilson S, Braziunas J, Greenfield S, Billimek J, Lechpammer S, Lin DW, Karsh L, Quinn DI, Shevrin D, Shore ND, Symanowski JT, Penson DF. Validating the total illness burden index for prostate cancer (TIBI-CaP) in men with castration-resistant prostate cancer: data from TRUMPET. Future Oncol. 2018 Mar; 14(6):527-536. PMID: 29417827.
      Citations:    
    48. Sahoo D, Wei W, Auman H, Hurtado-Coll A, Carroll PR, Fazli L, Gleave ME, Lin DW, Nelson PS, Simko J, Thompson IM, Leach RJ, Troyer DA, True LD, McKenney JK, Feng Z, Brooks JD. Boolean analysis identifies CD38 as a biomarker of aggressive localized prostate cancer. Oncotarget. 2018 Jan 19; 9(5):6550-6561. PMID: 29464091.
      Citations:    
    49. Schenk JM, Song X, Morrissey C, Vessella RL, Lin DW, Neuhouser ML. Plasma Fatty Acids as Surrogate for Prostate Levels. Nutr Cancer. 2018 Jan; 70(1):45-50. PMID: 29267025.
      Citations:    
    50. Giri VN, Knudsen KE, Kelly WK, Abida W, Andriole GL, Bangma CH, Bekelman JE, Benson MC, Blanco A, Burnett A, Catalona WJ, Cooney KA, Cooperberg M, Crawford DE, Den RB, Dicker AP, Eggener S, Fleshner N, Freedman ML, Hamdy FC, Hoffman-Censits J, Hurwitz MD, Hyatt C, Isaacs WB, Kane CJ, Kantoff P, Karnes RJ, Karsh LI, Klein EA, Lin DW, Loughlin KR, Lu-Yao G, Malkowicz SB, Mann MJ, Mark JR, McCue PA, Miner MM, Morgan T, Moul JW, Myers RE, Nielsen SM, Obeid E, Pavlovich CP, Peiper SC, Penson DF, Petrylak D, Pettaway CA, Pilarski R, Pinto PA, Poage W, Raj GV, Rebbeck TR, Robson ME, Rosenberg MT, Sandler H, Sartor O, Schaeffer E, Schwartz GF, Shahin MS, Shore ND, Shuch B, Soule HR, Tomlins SA, Trabulsi EJ, Uzzo R, Vander Griend DJ, Walsh PC, Weil CJ, Wender R, Gomella LG. Role of Genetic Testing for Inherited Prostate Cancer Risk: Philadelphia Prostate Cancer Consensus Conference 2017. J Clin Oncol. 2018 Feb 01; 36(4):414-424. PMID: 29236593.
      Citations:    
    51. Inoue LYT, Lin DW, Newcomb LF, Leonardson AS, Ankerst D, Gulati R, Carter HB, Trock BJ, Carroll PR, Cooperberg MR, Cowan JE, Klotz LH, Mamedov A, Penson DF, Etzioni R. Comparative Analysis of Biopsy Upgrading in Four Prostate Cancer Active Surveillance Cohorts. Ann Intern Med. 2018 Jan 02; 168(1):1-9. PMID: 29181514.
      Citations:    
    52. Winters BR, Kearns JT, Holt SK, Mossanen M, Lin DW, Wright JL. Is there a benefit to adjuvant radiation in stage III penile cancer after lymph node dissection? Findings from the National Cancer Database. Urol Oncol. 2018 Mar; 36(3):92.e11-92.e16. PMID: 29174944.
      Citations:    
    53. Cucchiara V, Cooperberg MR, Dall'Era M, Lin DW, Montorsi F, Schalken JA, Evans CP. Genomic Markers in Prostate Cancer Decision Making. Eur Urol. 2018 Apr; 73(4):572-582. PMID: 29129398.
      Citations:    
    54. Kearns JT, Lin DW. Prediction models for prostate cancer outcomes: what is the state of the art in 2017? Curr Opin Urol. 2017 Sep; 27(5):469-474. PMID: 28650863.
      Citations:    
    55. Sanda MG, Feng Z, Howard DH, Tomlins SA, Sokoll LJ, Chan DW, Regan MM, Groskopf J, Chipman J, Patil DH, Salami SS, Scherr DS, Kagan J, Srivastava S, Thompson IM, Siddiqui J, Fan J, Joon AY, Bantis LE, Rubin MA, Chinnayian AM, Wei JT, Bidair M, Kibel A, Lin DW, Lotan Y, Partin A, Taneja S. Association Between Combined TMPRSS2:ERG and PCA3 RNA Urinary Testing and Detection of Aggressive Prostate Cancer. JAMA Oncol. 2017 Aug 01; 3(8):1085-1093. PMID: 28520829.
      Citations:    
    56. Spratt DE, Dess RT, Zumsteg ZS, Lin DW, Tran PT, Morgan TM, Antonarakis ES, Nguyen PL, Ryan CJ, Sandler HM, Cooperberg MR, Posadas E, Feng FY. A Systematic Review and Framework for the Use of Hormone Therapy with Salvage Radiation Therapy for Recurrent Prostate Cancer. Eur Urol. 2018 Feb; 73(2):156-165. PMID: 28716370.
      Citations:    
    57. Bhindi B, Karnes RJ, Rangel LJ, Mason RJ, Gettman MT, Frank I, Tollefson MK, Lin DW, Thompson RH, Boorjian SA. Independent Validation of the American Joint Committee on Cancer 8th Edition Prostate Cancer Staging Classification. J Urol. 2017 Dec; 198(6):1286-1294. PMID: 28669765.
      Citations:    
    58. Cheng HH, Pritchard CC, Montgomery B, Lin DW, Nelson PS. Prostate Cancer Screening in a New Era of Genetics. Clin Genitourin Cancer. 2017 Dec; 15(6):625-628. PMID: 28697982.
      Citations:    
    59. Gore JL, du Plessis M, Santiago-Jiménez M, Yousefi K, Thompson DJS, Karsh L, Lane BR, Franks M, Chen DYT, Bandyk M, Bianco FJ, Brown G, Clark W, Kibel AS, Kim HL, Lowrance W, Manoharan M, Maroni P, Perrapato S, Sieber P, Trabulsi EJ, Waterhouse R, Davicioni E, Lotan Y, Lin DW. Decipher test impacts decision making among patients considering adjuvant and salvage treatment after radical prostatectomy: Interim results from the Multicenter Prospective PRO-IMPACT study. Cancer. 2017 Aug 01; 123(15):2850-2859. PMID: 28422278.
      Citations:    
    60. Buyyounouski MK, Choyke PL, McKenney JK, Sartor O, Sandler HM, Amin MB, Kattan MW, Lin DW. Prostate cancer - major changes in the American Joint Committee on Cancer eighth edition cancer staging manual. CA Cancer J Clin. 2017 May 06; 67(3):245-253. PMID: 28222223.
      Citations:    
    61. Metcalfe MJ, Smaldone MC, Lin DW, Aparicio AM, Chapin BF. Role of radical prostatectomy in metastatic prostate cancer: A review. Urol Oncol. 2017 Apr; 35(4):125-134. PMID: 28190749.
      Citations:    
    62. Yu EY, Lin DW. Avoiding Undertreatment of Aggressive Prostate Cancer by Early Use of Chemotherapy. JAMA Oncol. 2017 Jan 01; 3(1):13-14. PMID: 27812683.
      Citations:    
    63. Lin DW, Newcomb LF, Brown MD, Sjoberg DD, Dong Y, Brooks JD, Carroll PR, Cooperberg M, Dash A, Ellis WJ, Fabrizio M, Gleave ME, Morgan TM, Nelson PS, Thompson IM, Wagner AA, Zheng Y. Evaluating the Four Kallikrein Panel of the 4Kscore for Prediction of High-grade Prostate Cancer in Men in the Canary Prostate Active Surveillance Study. Eur Urol. 2017 Sep; 72(3):448-454. PMID: 27889277.
      Citations:    
    64. Eminaga O, Wei W, Hawley SJ, Auman H, Newcomb LF, Simko J, Hurtado-Coll A, Troyer DA, Carroll PR, Gleave ME, Lin DW, Nelson PS, Thompson IM, True LD, McKenney JK, Feng Z, Fazli L, Brooks JD. MUC1 Expression by Immunohistochemistry Is Associated with Adverse Pathologic Features in Prostate Cancer: A Multi-Institutional Study. PLoS One. 2016; 11(11):e0165236. PMID: 27846218.
      Citations:    
    65. Montgomery B, Tretiakova MS, Joshua AM, Gleave ME, Fleshner N, Bubley GJ, Mostaghel EA, Chi KN, Lin DW, Sanda M, Novotny W, Wu K, Kantoff PW, Marck BT, Plymate S, Balk SP, Nelson PS, Matsumoto AM, Lis RT, Kibel A, Haas GP, Krivoshik A, Hannah A, Taplin ME. Neoadjuvant Enzalutamide Prior to Prostatectomy. Clin Cancer Res. 2017 May 01; 23(9):2169-2176. PMID: 28151719.
      Citations:    
    66. McKenney JK, Wei W, Hawley S, Auman H, Newcomb LF, Boyer HD, Fazli L, Simko J, Hurtado-Coll A, Troyer DA, Tretiakova MS, Vakar-Lopez F, Carroll PR, Cooperberg MR, Gleave ME, Lance RS, Lin DW, Nelson PS, Thompson IM, True LD, Feng Z, Brooks JD. Histologic Grading of Prostatic Adenocarcinoma Can Be Further Optimized: Analysis of the Relative Prognostic Strength of Individual Architectural Patterns in 1275 Patients From the Canary Retrospective Cohort. Am J Surg Pathol. 2016 Nov; 40(11):1439-1456. PMID: 27635949.
      Citations:    
    67. Macleod LC, Ellis WJ, Newcomb LF, Zheng Y, Brooks JD, Carroll PR, Gleave ME, Lance RS, Nelson PS, Thompson IM, Wagner AA, Wei JT, Lin DW. Timing of Adverse Prostate Cancer Reclassification on First Surveillance Biopsy: Results from the Canary Prostate Cancer Active Surveillance Study. J Urol. 2017 04; 197(4):1026-1033. PMID: 27810448.
      Citations:    
    68. Rubicz R, Zhao S, Wright JL, Coleman I, Grasso C, Geybels MS, Leonardson A, Kolb S, April C, Bibikova M, Troyer D, Lance R, Lin DW, Ostrander EA, Nelson PS, Fan JB, Feng Z, Stanford JL. Gene expression panel predicts metastatic-lethal prostate cancer outcomes in men diagnosed with clinically localized prostate cancer. Mol Oncol. 2017 Feb; 11(2):140-150. PMID: 28145099.
      Citations:    
    69. Geybels MS, Wright JL, Bibikova M, Klotzle B, Fan JB, Zhao S, Feng Z, Ostrander EA, Lin DW, Nelson PS, Stanford JL. Epigenetic signature of Gleason score and prostate cancer recurrence after radical prostatectomy. Clin Epigenetics. 2016; 8:97. PMID: 27651837; PMCID: PMC5024414.
      Citations:    
    70. Penson DF, Lin DW, Karsh L, Quinn DI, Shevrin DH, Shore N, Symanowski JT, Brown B, Forer D, Wong EK, Flanders SC. Treatment registry for outcomes in patients with castration-resistant prostate cancer (TRUMPET): a methodology for real-world evidence and research. Future Oncol. 2016 Dec; 12(23):2689-2699. PMID: 27528114.
      Citations:    
    71. Osbun N, Winters B, Holt SK, Schade GR, Lin DW, Wright JL. Characteristics of Patients With Sertoli and Leydig Cell Testis Neoplasms From a National Population-Based Registry. Clin Genitourin Cancer. 2017 Apr; 15(2):e263-e266. PMID: 27594555.
      Citations:    
    72. Mossanen M, Holt S, Gore JL, Lin DW, Wright JL. 15 Years of penile cancer management in the United States: An analysis of the use of partial penectomy for localized disease and chemotherapy in the metastatic setting. Urol Oncol. 2016 12; 34(12):530.e1-530.e7. PMID: 27495001.
      Citations:    
    73. Winters BR, Mossanen M, Holt SK, Lin DW, Wright JL. Predictors of Nodal Upstaging in Clinical Node Negative Patients With Penile Carcinoma: A National Cancer Database Analysis. Urology. 2016 Oct; 96:29-34. PMID: 27450944.
      Citations:    
    74. Zhao S, Geybels MS, Leonardson A, Rubicz R, Kolb S, Yan Q, Klotzle B, Bibikova M, Hurtado-Coll A, Troyer D, Lance R, Lin DW, Wright JL, Ostrander EA, Fan JB, Feng Z, Stanford JL. Epigenome-Wide Tumor DNA Methylation Profiling Identifies Novel Prognostic Biomarkers of Metastatic-Lethal Progression in Men Diagnosed with Clinically Localized Prostate Cancer. Clin Cancer Res. 2017 Jan 01; 23(1):311-319. PMID: 27358489.
      Citations:    
    75. Brooks JD, Wei W, Pollack JR, West RB, Shin JH, Sunwoo JB, Hawley SJ, Auman H, Newcomb LF, Simko J, Hurtado-Coll A, Troyer DA, Carroll PR, Gleave ME, Lin DW, Nelson PS, Thompson IM, True LD, McKenney JK, Feng Z, Fazli L. Loss of Expression of AZGP1 Is Associated With Worse Clinical Outcomes in a Multi-Institutional Radical Prostatectomy Cohort. Prostate. 2016 11; 76(15):1409-19. PMID: 27325561.
      Citations:    
    76. Winters BR, Wright JL, Holt SK, Lin DW, Ellis WJ, Dalkin BL, Schade GR. Extreme Gleason Upgrading From Biopsy to Radical Prostatectomy: A Population-based Analysis. Urology. 2016 10; 96:148-155. PMID: 27313123.
      Citations:    
    77. Lotan TL, Wei W, Morais CL, Hawley ST, Fazli L, Hurtado-Coll A, Troyer D, McKenney JK, Simko J, Carroll PR, Gleave M, Lance R, Lin DW, Nelson PS, Thompson IM, True LD, Feng Z, Brooks JD. PTEN Loss as Determined by Clinical-grade Immunohistochemistry Assay Is Associated with Worse Recurrence-free Survival in Prostate Cancer. Eur Urol Focus. 2016 Jun; 2(2):180-188. PMID: 27617307.
      Citations:    
    78. Mossanen M, Macleod LC, Chu A, Wright JL, Dalkin B, Lin DW, True L, Gore JL. Comparative Effectiveness of a Patient Centered Pathology Report for Bladder Cancer Care. J Urol. 2016 Nov; 196(5):1383-1389. PMID: 27211289.
      Citations:    
    79. Lotan TL, Wei W, Ludkovski O, Morais CL, Guedes LB, Jamaspishvili T, Lopez K, Hawley ST, Feng Z, Fazli L, Hurtado-Coll A, McKenney JK, Simko J, Carroll PR, Gleave M, Lin DW, Nelson PS, Thompson IM, True LD, Brooks JD, Lance R, Troyer D, Squire JA. Analytic validation of a clinical-grade PTEN immunohistochemistry assay in prostate cancer by comparison with PTEN FISH. Mod Pathol. 2016 08; 29(8):904-14. PMID: 27174589.
      Citations:    
    80. Thirumalai A, Cooper LA, Rubinow KB, Amory JK, Lin DW, Wright JL, Marck BT, Matsumoto AM, Page ST. Stable Intraprostatic Dihydrotestosterone in Healthy Medically Castrate Men Treated With Exogenous Testosterone. J Clin Endocrinol Metab. 2016 Jul; 101(7):2937-44. PMID: 27172434; PMCID: PMC4929843.
      Citations:    
    81. Shui IM, Wong CJ, Zhao S, Kolb S, Ebot EM, Geybels MS, Rubicz R, Wright JL, Lin DW, Klotzle B, Bibikova M, Fan JB, Ostrander EA, Feng Z, Stanford JL. Prostate tumor DNA methylation is associated with cigarette smoking and adverse prostate cancer outcomes. Cancer. 2016 07 15; 122(14):2168-77. PMID: 27142338.
      Citations:    
    82. Macleod LC, Rajanahally S, Nayak JG, Parent BA, Ramos JD, Schade GR, Holt SK, Dash A, Gore JL, Lin DW. Characterizing the Morbidity of Postchemotherapy Retroperitoneal Lymph Node Dissection for Testis Cancer in a National Cohort of Privately Insured Patients. Urology. 2016 05; 91:70-6. PMID: 26802801.
      Citations:    
    83. Winters BR, Bremjit PJ, Gore JL, Lin DW, Ellis WJ, Dalkin BL, Porter MP, Harper JD, Wright JL. Preliminary Comparative Effectiveness of Robotic Versus Open Radical Cystectomy in Elderly Patients. J Endourol. 2016 Feb; 30(2):212-7. PMID: 26414964.
      Citations:    
    84. Newcomb LF, Thompson IM, Boyer HD, Brooks JD, Carroll PR, Cooperberg MR, Dash A, Ellis WJ, Fazli L, Feng Z, Gleave ME, Kunju P, Lance RS, McKenney JK, Meng MV, Nicolas MM, Sanda MG, Simko J, So A, Tretiakova MS, Troyer DA, True LD, Vakar-Lopez F, Virgin J, Wagner AA, Wei JT, Zheng Y, Nelson PS, Lin DW. Outcomes of Active Surveillance for Clinically Localized Prostate Cancer in the Prospective, Multi-Institutional Canary PASS Cohort. J Urol. 2016 Feb; 195(2):313-20. PMID: 26327354; PMCID: PMC4970462.
      Citations:    
    85. Winters BR, Gore JL, Holt SK, Harper JD, Lin DW, Wright JL. Cystic renal cell carcinoma carries an excellent prognosis regardless of tumor size. Urol Oncol. 2015 Dec; 33(12):505.e9-13. PMID: 26319351; PMCID: PMC4843506.
      Citations:    
    86. Winters B, Plymate S, Zeliadt SB, Holt S, Zhang X, Hu E, Lin DW, Morrissey C, Wooldridge B, Gore JL, Porter MP, Wright JL. Metformin effects on biochemical recurrence and metabolic signaling in the prostate. Prostate. 2015 Nov; 75(15):1694-703. PMID: 26201966; PMCID: PMC4578998.
      Citations:    
    87. Macleod LC, Tykodi SS, Holt SK, Wright JL, Lin DW, Tretiakova MS, True LD, Gore JL. Trends in Metastatic Kidney Cancer Survival From the Cytokine to the Targeted Therapy Era. Urology. 2015 Aug; 86(2):262-8. PMID: 26199164.
      Citations:    
    88. Brooks JD, Wei W, Hawley S, Auman H, Newcomb L, Boyer H, Fazli L, Simko J, Hurtado-Coll A, Troyer DA, Carroll PR, Gleave M, Lance R, Lin DW, Nelson PS, Thompson IM, True LD, Feng Z, McKenney JK. Evaluation of ERG and SPINK1 by Immunohistochemical Staining and Clinicopathological Outcomes in a Multi-Institutional Radical Prostatectomy Cohort of 1067 Patients. PLoS One. 2015; 10(7):e0132343. PMID: 26172920; PMCID: PMC4501723.
      Citations:    
    89. Morgans AK, van Bommel AC, Stowell C, Abrahm JL, Basch E, Bekelman JE, Berry DL, Bossi A, Davis ID, de Reijke TM, Denis LJ, Evans SM, Fleshner NE, George DJ, Kiefert J, Lin DW, Matthew AG, McDermott R, Payne H, Roos IA, Schrag D, Steuber T, Tombal B, van Basten JP, van der Hoeven JJ, Penson DF. Development of a Standardized Set of Patient-centered Outcomes for Advanced Prostate Cancer: An International Effort for a Unified Approach. Eur Urol. 2015 Nov; 68(5):891-8. PMID: 26129856.
      Citations:    
    90. Lin DW. Testicular Cancer. Preface. Urol Clin North Am. 2015 Aug; 42(3):xvii. PMID: 26216829.
      Citations:    
    91. Motzer RJ, Jonasch E, Agarwal N, Beard C, Bhayani S, Bolger GB, Chang SS, Choueiri TK, Costello BA, Derweesh IH, Gupta S, Hancock SL, Kim JJ, Kuzel TM, Lam ET, Lau C, Levine EG, Lin DW, Michaelson MD, Olencki T, Pili R, Plimack ER, Rampersaud EN, Redman BG, Ryan CJ, Sheinfeld J, Shuch B, Sircar K, Somer B, Wilder RB, Dwyer M, Kumar R. Testicular Cancer, Version 2.2015. J Natl Compr Canc Netw. 2015 Jun; 13(6):772-99. PMID: 26085393.
      Citations:    
    92. Rubicz R, Zhao S, April C, Wright JL, Kolb S, Coleman I, Lin DW, Nelson PS, Ostrander EA, Feng Z, Fan JB, Stanford JL. Expression of cell cycle-regulated genes and prostate cancer prognosis in a population-based cohort. Prostate. 2015 Sep; 75(13):1354-62. PMID: 25990700; PMCID: PMC4992473.
      Citations:    
    93. Troyer DA, Jamaspishvili T, Wei W, Feng Z, Good J, Hawley S, Fazli L, McKenney JK, Simko J, Hurtado-Coll A, Carroll PR, Gleave M, Lance R, Lin DW, Nelson PS, Thompson IM, True LD, Brooks JD, Squire JA. A multicenter study shows PTEN deletion is strongly associated with seminal vesicle involvement and extracapsular extension in localized prostate cancer. Prostate. 2015 Aug 01; 75(11):1206-15. PMID: 25939393.
      Citations:    
    94. Ankerst DP, Xia J, Thompson IM, Hoefler J, Newcomb LF, Brooks JD, Carroll PR, Ellis WJ, Gleave ME, Lance RS, Nelson PS, Wagner AA, Wei JT, Etzioni R, Lin DW. Precision Medicine in Active Surveillance for Prostate Cancer: Development of the Canary-Early Detection Research Network Active Surveillance Biopsy Risk Calculator. Eur Urol. 2015 Dec; 68(6):1083-8. PMID: 25819722; PMCID: PMC4583313.
      Citations:    
    95. Etzioni R, Gulati R, Lin DW. Measures of survival benefit in cancer drug development and their limitations. Urol Oncol. 2015 Mar; 33(3):122-7. PMID: 25813143; PMCID: PMC4403641.
      Citations:    
    96. Motzer RJ, Jonasch E, Agarwal N, Beard C, Bhayani S, Bolger GB, Chang SS, Choueiri TK, Costello BA, Derweesh IH, Gupta S, Hancock SL, Kim JJ, Kuzel TM, Lam ET, Lau C, Levine EG, Lin DW, Michaelson MD, Olencki T, Pili R, Plimack ER, Rampersaud EN, Redman BG, Ryan CJ, Sheinfeld J, Shuch B, Sircar K, Somer B, Wilder RB, Dwyer M, Kumar R. Kidney cancer, version 3.2015. J Natl Compr Canc Netw. 2015 Feb; 13(2):151-9. PMID: 25691606.
      Citations:    
    97. Delahunt B, Hammond E, Egevad L, Samaratunga H, Srigley JR, Humphrey PA, Rubin M, Epstein JI, Lin DW, Gore JL, Nacey JN, Klotz L, Sandler H, Zietman AL, Holden S, Montironi R, Evans AJ, McKenney JK, Berney D, Wheeler TM, Chinnaiyan AM, True L, Knudsen B, Amin MB. Active surveillance for prostate cancer: the role of the pathologist. Pathology. 2015 Jan; 47(1):1-3. PMID: 25474525.
      Citations:    
    98. Wei JT, Feng Z, Partin AW, Brown E, Thompson I, Sokoll L, Chan DW, Lotan Y, Kibel AS, Busby JE, Bidair M, Lin DW, Taneja SS, Viterbo R, Joon AY, Dahlgren J, Kagan J, Srivastava S, Sanda MG. Can urinary PCA3 supplement PSA in the early detection of prostate cancer? J Clin Oncol. 2014 Dec 20; 32(36):4066-72. PMID: 25385735; PMCID: PMC4265117.
      Citations:    
    99. Parekh DJ, Punnen S, Sjoberg DD, Asroff SW, Bailen JL, Cochran JS, Concepcion R, David RD, Deck KB, Dumbadze I, Gambla M, Grable MS, Henderson RJ, Karsh L, Krisch EB, Langford TD, Lin DW, McGee SM, Munoz JJ, Pieczonka CM, Rieger-Christ K, Saltzstein DR, Scott JW, Shore ND, Sieber PR, Waldmann TM, Wolk FN, Zappala SM. A multi-institutional prospective trial in the USA confirms that the 4Kscore accurately identifies men with high-grade prostate cancer. Eur Urol. 2015 Sep; 68(3):464-70. PMID: 25454615.
      Citations:    
    100. Montironi R, Hammond EH, Lin DW, Gore JL, Srigley JR, Samaratunga H, Egevad L, Rubin MA, Nacey J, Klotz L, Sandler H, Zietman AL, Holden S, Humphrey PA, Evans AJ, Delahunt B, McKenney JK, Berney D, Wheeler TM, Chinnaiyan A, True L, Knudsen B, Epstein JI, Amin MB. Consensus statement with recommendations on active surveillance inclusion criteria and definition of progression in men with localized prostate cancer: the critical role of the pathologist. Virchows Arch. 2014 Dec; 465(6):623-8. PMID: 25316188.
      Citations:    
    101. Brockman JA, Alanee S, Vickers AJ, Scardino PT, Wood DP, Kibel AS, Lin DW, Bianco FJ, Rabah DM, Klein EA, Ciezki JP, Gao T, Kattan MW, Stephenson AJ. Nomogram Predicting Prostate Cancer-specific Mortality for Men with Biochemical Recurrence After Radical Prostatectomy. Eur Urol. 2015 Jun; 67(6):1160-1167. PMID: 25301759; PMCID: PMC4779062.
      Citations:    
    102. Amin MB, Lin DW, Gore JL, Srigley JR, Samaratunga H, Egevad L, Rubin M, Nacey J, Carter HB, Klotz L, Sandler H, Zietman AL, Holden S, Montironi R, Humphrey PA, Evans AJ, Epstein JI, Delahunt B, McKenney JK, Berney D, Wheeler TM, Chinnaiyan AM, True L, Knudsen B, Hammond ME. The critical role of the pathologist in determining eligibility for active surveillance as a management option in patients with prostate cancer: consensus statement with recommendations supported by the College of American Pathologists, International Society of Urological Pathology, Association of Directors of Anatomic and Surgical Pathology, the New Zealand Society of Pathologists, and the Prostate Cancer Foundation. Arch Pathol Lab Med. 2014 Oct; 138(10):1387-405. PMID: 25092589.
      Citations:    
    103. James AC, Lin DW, Wright JL. Neobladders and continent catheterizable stomas for the bladder cancer survivor. Curr Opin Urol. 2014 Jul; 24(4):407-14. PMID: 24841376.
      Citations:    
    104. Mossanen M, Calvert JK, Wright JL, True LD, Lin DW, Gore JL. Readability of urologic pathology reports: the need for patient-centered approaches. Urol Oncol. 2014 Nov; 32(8):1091-4. PMID: 24846343.
      Citations:    
    105. Mostaghel EA, Lin DW. Practical guide to the use of abiraterone in castration resistant prostate cancer. Can J Urol. 2014 Apr; 21(2 Supp 1):57-63. PMID: 24775725; PMCID: PMC4139288.
      Citations:    
    106. Lin DW. Editorial comment. Urology. 2014 May; 83(5):978-9. PMID: 24661330.
      Citations:    
    107. Izard JP, True LD, May P, Ellis WJ, Lange PH, Dalkin B, Lin DW, Schmidt RA, Wright JL. Prostate cancer that is within 0.1 mm of the surgical margin of a radical prostatectomy predicts greater likelihood of recurrence. Am J Surg Pathol. 2014 Mar; 38(3):333-8. PMID: 24525503; PMCID: PMC4428570.
      Citations:    
    108. Motzer RJ, Jonasch E, Agarwal N, Beard C, Bhayani S, Bolger GB, Chang SS, Choueiri TK, Derweesh IH, Gupta S, Hancock SL, Kim JJ, Kuzel TM, Lam ET, Lau C, Levine EG, Lin DW, Margolin KA, Michaelson MD, Olencki T, Pili R, Plimack ER, Rampersaud EN, Redman BG, Ryan CJ, Sheinfeld J, Sircar K, Somer B, Wang J, Wilder RB, Dwyer MA, Kumar R. Kidney cancer, version 2.2014. J Natl Compr Canc Netw. 2014 Feb; 12(2):175-82. PMID: 24586079.
      Citations:    
    109. James AC, Lee FC, Izard JP, Harris WP, Cheng HH, Zhao S, Gore JL, Lin DW, Porter MP, Yu EY, Wright JL. Role of maximal endoscopic resection before cystectomy for invasive urothelial bladder cancer. Clin Genitourin Cancer. 2014 Aug; 12(4):287-91. PMID: 24560087.
      Citations:    
    110. Quinn DI, Vaishampayan U, Higano CS, Lin DW, Shore ND, Beer TM. Sequencing therapy in advanced prostate cancer: focus on sipuleucel-T. Expert Rev Anticancer Ther. 2014 Jan; 14(1):51-61. PMID: 24224900.
      Citations:    
    111. Mostaghel EA, Nelson PS, Lange P, Lin DW, Taplin ME, Balk S, Ellis W, Kantoff P, Marck B, Tamae D, Matsumoto AM, True LD, Vessella R, Penning T, Hunter Merrill R, Gulati R, Montgomery B. Targeted androgen pathway suppression in localized prostate cancer: a pilot study. J Clin Oncol. 2014 Jan 20; 32(3):229-37. PMID: 24323034; PMCID: PMC3887479.
      Citations:    
    112. Wright JL, Izard JP, Lin DW. Surgical management of prostate cancer. Hematol Oncol Clin North Am. 2013 Dec; 27(6):1111-35, vii. PMID: 24188255.
      Citations:    
    113. Lee F, Gottsch H, Ellis WJ, True LD, Lin DW, Wright JL. Differences in Upgrading of Prostate Cancer in Prostatectomies between Community and Academic Practices. Adv Urol. 2013; 2013:471234. PMID: 24260032; PMCID: PMC3821894.
      Citations:    
    114. Izard JP, Salazar MA, Chatterjee S, Lin DW, Wright JL. Positive surgical margins at radical prostatectomy: Population-based averages within PSA and Gleason strata. Can Urol Assoc J. 2013 Sep-Oct; 7(9-10):E561-6. PMID: 24069096; PMCID: PMC3776029.
      Citations:    
    115. Wright JL, Plymate S, D'Oria-Cameron A, Bain C, Haugk K, Xiao L, Lin DW, Stanford JL, McTiernan A. A study of caloric restriction versus standard diet in overweight men with newly diagnosed prostate cancer: a randomized controlled trial. Prostate. 2013 Sep; 73(12):1345-51. PMID: 23775525; PMCID: PMC3767289.
      Citations:    
    116. Cookson MS, Roth BJ, Dahm P, Engstrom C, Freedland SJ, Hussain M, Lin DW, Lowrance WT, Murad MH, Oh WK, Penson DF, Kibel AS. Castration-resistant prostate cancer: AUA Guideline. J Urol. 2013 Aug; 190(2):429-38. PMID: 23665272.
      Citations:    
    117. Donat SM, Diaz M, Bishoff JT, Coleman JA, Dahm P, Derweesh IH, Herrell SD, Hilton S, Jonasch E, Lin DW, Reuter VE, Chang SS. Follow-up for Clinically Localized Renal Neoplasms: AUA Guideline. J Urol. 2013 Aug; 190(2):407-16. PMID: 23665399.
      Citations:    
    118. Dean JP, Sprenger CC, Wan J, Haugk K, Ellis WJ, Lin DW, Corman JM, Dalkin BL, Mostaghel E, Nelson PS, Cohen P, Montgomery B, Plymate SR. Response of the insulin-like growth factor (IGF) system to IGF-IR inhibition and androgen deprivation in a neoadjuvant prostate cancer trial: effects of obesity and androgen deprivation. J Clin Endocrinol Metab. 2013 May; 98(5):E820-8. PMID: 23533230; PMCID: PMC4430583.
      Citations:    
    119. Lin DW, Newcomb LF, Brown EC, Brooks JD, Carroll PR, Feng Z, Gleave ME, Lance RS, Sanda MG, Thompson IM, Wei JT, Nelson PS. Urinary TMPRSS2:ERG and PCA3 in an active surveillance cohort: results from a baseline analysis in the Canary Prostate Active Surveillance Study. Clin Cancer Res. 2013 May 01; 19(9):2442-50. PMID: 23515404; PMCID: PMC3674574.
      Citations:    
    120. Xia J, Gulati R, Au M, Gore JL, Lin DW, Etzioni R. Effects of screening on radical prostatectomy efficacy: the prostate cancer intervention versus observation trial. J Natl Cancer Inst. 2013 Apr 17; 105(8):546-50. PMID: 23411592; PMCID: PMC3691943.
      Citations:    
    121. Zeliadt SB, Hannon PA, Trivedi RB, Bonner LM, Vu TT, Simons C, Kimmie CA, Hu EY, Zipperer C, Lin DW. A preliminary exploration of the feasibility of offering men information about potential prostate cancer treatment options before they know their biopsy results. BMC Med Inform Decis Mak. 2013 Feb 06; 13:19. PMID: 23388205; PMCID: PMC3599913.
      Citations:    
    122. Hawley S, Fazli L, McKenney JK, Simko J, Troyer D, Nicolas M, Newcomb LF, Cowan JE, Crouch L, Ferrari M, Hernandez J, Hurtado-Coll A, Kuchinsky K, Liew J, Mendez-Meza R, Smith E, Tenggara I, Zhang X, Carroll PR, Chan JM, Gleave M, Lance R, Lin DW, Nelson PS, Thompson IM, Feng Z, True LD, Brooks JD. A model for the design and construction of a resource for the validation of prognostic prostate cancer biomarkers: the Canary Prostate Cancer Tissue Microarray. Adv Anat Pathol. 2013 Jan; 20(1):39-44. PMID: 23232570.
      Citations:    
    123. Truong M, Yang B, Livermore A, Wagner J, Weeratunga P, Huang W, Dhir R, Nelson J, Lin DW, Jarrard DF. Using the epigenetic field defect to detect prostate cancer in biopsy negative patients. J Urol. 2013 Jun; 189(6):2335-41. PMID: 23159584.
      Citations:    
    124. Hu JC, Lin DW. Current status of focal primary therapy for prostate cancer. Urol Oncol. 2012 Nov-Dec; 30(6):942-3. PMID: 23218072.
      Citations:    
    125. Brimo F, Montironi R, Egevad L, Erbersdobler A, Lin DW, Nelson JB, Rubin MA, van der Kwast T, Amin M, Epstein JI. Contemporary grading for prostate cancer: implications for patient care. Eur Urol. 2013 May; 63(5):892-901. PMID: 23092544.
      Citations:    
    126. Xia J, Trock BJ, Cooperberg MR, Gulati R, Zeliadt SB, Gore JL, Lin DW, Carroll PR, Carter HB, Etzioni R. Prostate cancer mortality following active surveillance versus immediate radical prostatectomy. Clin Cancer Res. 2012 Oct 01; 18(19):5471-8. PMID: 23008476; PMCID: PMC3604990.
      Citations:    
    127. Cheng HH, Lin DW, Yu EY. Advanced clinical states in prostate cancer. Urol Clin North Am. 2012 Nov; 39(4):561-71. PMID: 23084531.
      Citations:    
    128. Lin DW, Shore ND. The changing landscape of urologic oncology: initiating systemic therapies, interventional skills, and clinical trials. Introduction. Urol Oncol. 2012 Jul-Aug; 30(4 Suppl):S1. PMID: 22795074.
      Citations:    
    129. Mostaghel EA, Lin DW, Amory JK, Wright JL, Marck BT, Nelson PS, Matsumoto AM, Bremner WJ, Page ST. Impact of male hormonal contraception on prostate androgens and androgen action in healthy men: a randomized, controlled trial. J Clin Endocrinol Metab. 2012 Aug; 97(8):2809-17. PMID: 22659250; PMCID: PMC3410271.
      Citations:    
    130. Motzer RJ, Agarwal N, Beard C, Bhayani S, Bolger GB, Buyyounouski MK, Carducci MA, Chang SS, Choueiri TK, Gupta S, Hancock SL, Hudes GR, Jonasch E, Kuzel TM, Lau C, Levine EG, Lin DW, Margolin KA, Michaelson MD, Olencki T, Pili R, Ratliff TW, Redman BG, Robertson CN, Ryan CJ, Sheinfeld J, Wang J, Wilder RB. Testicular cancer. J Natl Compr Canc Netw. 2012 Apr; 10(4):502-35. PMID: 22491049.
      Citations:    
    131. Wright JL, Lin DW, Stanford JL. Circumcision and the risk of prostate cancer. Cancer. 2012 Sep 15; 118(18):4437-43. PMID: 22411189; PMCID: PMC3376675.
      Citations:    
    132. Berry DL, Halpenny B, Hong F, Wolpin S, Lober WB, Russell KJ, Ellis WJ, Govindarajulu U, Bosco J, Davison BJ, Bennett G, Terris MK, Barsevick A, Lin DW, Yang CC, Swanson G. The Personal Patient Profile-Prostate decision support for men with localized prostate cancer: a multi-center randomized trial. Urol Oncol. 2013 Oct; 31(7):1012-21. PMID: 22153756.
      Citations:    
    133. Motzer RJ, Agarwal N, Beard C, Bhayani S, Bolger GB, Carducci MA, Chang SS, Choueiri TK, Hancock SL, Hudes GR, Jonasch E, Josephson D, Kuzel TM, Levine EG, Lin DW, Margolin KA, Michaelson MD, Olencki T, Pili R, Ratliff TW, Redman BG, Robertson CN, Ryan CJ, Sheinfeld J, Spiess PE, Wang J, Wilder RB. Kidney cancer. J Natl Compr Canc Netw. 2011 Sep 01; 9(9):960-77. PMID: 21917622.
      Citations:    
    134. Lin DW, FitzGerald LM, Fu R, Kwon EM, Zheng SL, Kolb S, Wiklund F, Stattin P, Isaacs WB, Xu J, Ostrander EA, Feng Z, Grönberg H, Stanford JL. Genetic variants in the LEPR, CRY1, RNASEL, IL4, and ARVCF genes are prognostic markers of prostate cancer-specific mortality. Cancer Epidemiol Biomarkers Prev. 2011 Sep; 20(9):1928-36. PMID: 21846818; PMCID: PMC3169727.
      Citations:    
    135. Wyman SK, Knouf EC, Parkin RK, Fritz BR, Lin DW, Dennis LM, Krouse MA, Webster PJ, Tewari M. Post-transcriptional generation of miRNA variants by multiple nucleotidyl transferases contributes to miRNA transcriptome complexity. Genome Res. 2011 Sep; 21(9):1450-61. PMID: 21813625; PMCID: PMC3166830.
      Citations:    
    136. Gore JL, Wright JL, Daratha KB, Roberts KP, Lin DW, Wessells H, Porter M. Hospital-level variation in the quality of urologic cancer surgery. Cancer. 2012 Feb 15; 118(4):987-96. PMID: 21792864; PMCID: PMC3273633.
      Citations:    
    137. George DJ, Kantoff PW, Lin DW. Clinical roundtable monograph: new and emerging treatments for advanced prostate cancer. Clin Adv Hematol Oncol. 2011 Jun; 9(6):1-11; discussion 11-5. PMID: 21941983.
      Citations:    
    138. George DJ, Kantoff PW, Lin DW. New and emerging treatments for advanced prostate cancer. Clin Adv Hematol Oncol. 2011 Jun; 9(6 Suppl 12):1-15. PMID: 22361744.
      Citations:    
    139. Schenk JM, Kristal AR, Arnold KB, Tangen CM, Neuhouser ML, Lin DW, White E, Thompson IM. Association of symptomatic benign prostatic hyperplasia and prostate cancer: results from the prostate cancer prevention trial. Am J Epidemiol. 2011 Jun 15; 173(12):1419-28. PMID: 21540324; PMCID: PMC3276227.
      Citations:    
    140. Wright JL, Lin DW, Stanford JL. The effect of demographic and clinical factors on the relationship between BMI and PSA levels. Prostate. 2011 Nov; 71(15):1631-7. PMID: 21432865; PMCID: PMC3409087.
      Citations:    
    141. Zeliadt SB, Hoffman RM, Etzioni R, Gore JL, Kessler LG, Lin DW. Influence of publication of US and European prostate cancer screening trials on PSA testing practices. J Natl Cancer Inst. 2011 Mar 16; 103(6):520-3. PMID: 21357307.
      Citations:    
    142. Wright JL, Kwon EM, Ostrander EA, Montgomery RB, Lin DW, Vessella R, Stanford JL, Mostaghel EA. Expression of SLCO transport genes in castration-resistant prostate cancer and impact of genetic variation in SLCO1B3 and SLCO2B1 on prostate cancer outcomes. Cancer Epidemiol Biomarkers Prev. 2011 Apr; 20(4):619-27. PMID: 21266523; PMCID: PMC3073610.
      Citations:    
    143. Morgan TM, Welty CJ, Vakar-Lopez F, Lin DW, Wright JL. Ductal adenocarcinoma of the prostate: increased mortality risk and decreased serum prostate specific antigen. J Urol. 2010 Dec; 184(6):2303-7. PMID: 20952027; PMCID: PMC3111052.
      Citations:    
    144. Wright JL, Neuhouser ML, Lin DW, Kwon EM, Feng Z, Ostrander EA, Stanford JL. AMACR polymorphisms, dietary intake of red meat and dairy and prostate cancer risk. Prostate. 2011 Apr; 71(5):498-506. PMID: 20945498; PMCID: PMC3148811.
      Citations:    
    145. Risk MC, Knudsen BS, Coleman I, Dumpit RF, Kristal AR, LeMeur N, Gentleman RC, True LD, Nelson PS, Lin DW. Differential gene expression in benign prostate epithelium of men with and without prostate cancer: evidence for a prostate cancer field effect. Clin Cancer Res. 2010 Nov 15; 16(22):5414-23. PMID: 20935156; PMCID: PMC2992073.
      Citations:    
    146. Holt SK, Kwon EM, Koopmeiners JS, Lin DW, Feng Z, Ostrander EA, Peters U, Stanford JL. Vitamin D pathway gene variants and prostate cancer prognosis. Prostate. 2010 Sep 15; 70(13):1448-60. PMID: 20687218; PMCID: PMC2927712.
      Citations:    
    147. Zeliadt SB, Hoffman RM, Etzioni R, Ginger VA, Lin DW. What happens after an elevated PSA test: the experience of 13,591 veterans. J Gen Intern Med. 2010 Nov; 25(11):1205-10. PMID: 20697965; PMCID: PMC2947635.
      Citations:    
    148. Wright JL, Kwon EM, Lin DW, Kolb S, Koopmeiners JS, Feng Z, Ostrander EA, Stanford JL. CYP17 polymorphisms and prostate cancer outcomes. Prostate. 2010 Jul 01; 70(10):1094-101. PMID: 20503394; PMCID: PMC2878282.
      Citations:    
    149. Holt SK, Kwon EM, Lin DW, Ostrander EA, Stanford JL. Association of hepsin gene variants with prostate cancer risk and prognosis. Prostate. 2010 Jun 15; 70(9):1012-9. PMID: 20166135; PMCID: PMC2875316.
      Citations:    
    150. Wright JL, Dalkin BL, True LD, Ellis WJ, Stanford JL, Lange PH, Lin DW. Positive surgical margins at radical prostatectomy predict prostate cancer specific mortality. J Urol. 2010 Jun; 183(6):2213-8. PMID: 20399459; PMCID: PMC2903223.
      Citations:    
    151. Kristal AR, Price DK, Till C, Schenk JM, Neuhouser ML, Ockers S, Lin DW, Thompson IM, Figg WD. Androgen receptor CAG repeat length is not associated with the risk of incident symptomatic benign prostatic hyperplasia: results from the Prostate Cancer Prevention Trial. Prostate. 2010 May 01; 70(6):584-90. PMID: 19938041; PMCID: PMC3904425.
      Citations:    
    152. Wright JL, Page ST, Lin DW, Stanford JL. Male pattern baldness and prostate cancer risk in a population-based case-control study. Cancer Epidemiol. 2010 Apr; 34(2):131-5. PMID: 20206591; PMCID: PMC2911123.
      Citations:    
    153. Schenk JM, Kristal AR, Neuhouser ML, Tangen CM, White E, Lin DW, Kratz M, Thompson IM. Biomarkers of systemic inflammation and risk of incident, symptomatic benign prostatic hyperplasia: results from the prostate cancer prevention trial. Am J Epidemiol. 2010 Mar 01; 171(5):571-82. PMID: 20142396; PMCID: PMC2842217.
      Citations:    
    154. Wright JL, Salinas CA, Lin DW, Kolb S, Koopmeiners J, Feng Z, Stanford JL. Prostate cancer specific mortality and Gleason 7 disease differences in prostate cancer outcomes between cases with Gleason 4 + 3 and Gleason 3 + 4 tumors in a population based cohort. J Urol. 2009 Dec; 182(6):2702-7. PMID: 19836772; PMCID: PMC2828768.
      Citations:    
    155. Wright JL, Risk MC, Hotaling J, Lin DW. Effect of collecting duct histology on renal cell cancer outcome. J Urol. 2009 Dec; 182(6):2595-9. PMID: 19836761; PMCID: PMC2828767.
      Citations:    
    156. Takata Y, Morris JS, King IB, Kristal AR, Lin DW, Peters U. Correlation between selenium concentrations and glutathione peroxidase activity in serum and human prostate tissue. Prostate. 2009 Nov 01; 69(15):1635-42. PMID: 19623542; PMCID: PMC3166332.
      Citations:    
    157. Newcomb LF, Brooks JD, Carroll PR, Feng Z, Gleave ME, Nelson PS, Thompson IM, Lin DW. Canary Prostate Active Surveillance Study: design of a multi-institutional active surveillance cohort and biorepository. Urology. 2010 Feb; 75(2):407-13. PMID: 19758683; PMCID: PMC3827723.
      Citations:    
    158. Schenk JM, Kristal AR, Neuhouser ML, Tangen CM, White E, Lin DW, Thompson IM. Serum adiponectin, C-peptide and leptin and risk of symptomatic benign prostatic hyperplasia: results from the Prostate Cancer Prevention Trial. Prostate. 2009 Sep 01; 69(12):1303-11. PMID: 19475640; PMCID: PMC2838168.
      Citations:    
    159. Lin DW, Porter M, Montgomery B. Treatment and survival outcomes in young men diagnosed with prostate cancer: a Population-based Cohort Study. Cancer. 2009 Jul 01; 115(13):2863-71. PMID: 19466697; PMCID: PMC2948666.
      Citations:    
    160. Pomerantz MM, Beckwith CA, Regan MM, Wyman SK, Petrovics G, Chen Y, Hawksworth DJ, Schumacher FR, Mucci L, Penney KL, Stampfer MJ, Chan JA, Ardlie KG, Fritz BR, Parkin RK, Lin DW, Dyke M, Herman P, Lee S, Oh WK, Kantoff PW, Tewari M, McLeod DG, Srivastava S, Freedman ML. Evaluation of the 8q24 prostate cancer risk locus and MYC expression. Cancer Res. 2009 Jul 01; 69(13):5568-74. PMID: 19549893; PMCID: PMC2884104.
      Citations:    
    161. Risk MC, Lin DW. New and novel markers for prostate cancer detection. Curr Urol Rep. 2009 May; 10(3):179-86. PMID: 19371474.
      Citations:    
    162. Lin DW. Beyond PSA: utility of novel tumor markers in the setting of elevated PSA. Urol Oncol. 2009 May-Jun; 27(3):315-21. PMID: 19414121.
      Citations:    
    163. Salinas CA, Koopmeiners JS, Kwon EM, FitzGerald L, Lin DW, Ostrander EA, Feng Z, Stanford JL. Clinical utility of five genetic variants for predicting prostate cancer risk and mortality. Prostate. 2009 Mar 01; 69(4):363-72. PMID: 19058137; PMCID: PMC2788301.
      Citations:    
    164. Wu JD, Lin DW, Page ST, Lundgren AD, True LD, Plymate SR. Oxidative DNA damage in the prostate may predispose men to a higher risk of prostate cancer. Transl Oncol. 2009 Mar; 2(1):39-45. PMID: 19252750; PMCID: PMC2647701.
      Citations:    
    165. Schenk JM, Neuhouser ML, Lin DW, Kristal AR. A dietary intervention to elicit rapid and complex dietary changes for studies investigating the effects of diet on tissues collected during invasive surgical procedures. J Am Diet Assoc. 2009 Mar; 109(3):459-63. PMID: 19248862; PMCID: PMC3857024.
      Citations:    
    166. Morgan TM, Lange PH, Porter MP, Lin DW, Ellis WJ, Gallaher IS, Vessella RL. Disseminated tumor cells in prostate cancer patients after radical prostatectomy and without evidence of disease predicts biochemical recurrence. Clin Cancer Res. 2009 Jan 15; 15(2):677-83. PMID: 19147774; PMCID: PMC3162324.
      Citations:    
    167. Kristal AR, Schenk JM, Song Y, Arnold KB, Neuhouser ML, Goodman PJ, Lin DW, Stanczyk FZ, Thompson IM. Serum steroid and sex hormone-binding globulin concentrations and the risk of incident benign prostatic hyperplasia: results from the prostate cancer prevention trial. Am J Epidemiol. 2008 Dec 15; 168(12):1416-24. PMID: 18945688; PMCID: PMC2727187.
      Citations:    
    168. Wright JL, Morgan TM, Lin DW. Primary scrotal cancer: disease characteristics and increasing incidence. Urology. 2008 Nov; 72(5):1139-43. PMID: 18799208.
      Citations:    
    169. Trabulsi EJ, Valicenti RK, Hanlon AL, Pisansky TM, Sandler HM, Kuban DA, Catton CN, Michalski JM, Zelefsky MJ, Kupelian PA, Lin DW, Anscher MS, Slawin KM, Roehrborn CG, Forman JD, Liauw SL, Kestin LL, DeWeese TL, Scardino PT, Stephenson AJ, Pollack A. A multi-institutional matched-control analysis of adjuvant and salvage postoperative radiation therapy for pT3-4N0 prostate cancer. Urology. 2008 Dec; 72(6):1298-302; discussion 1302-4. PMID: 18672274.
      Citations:    
    170. Mitchell PS, Parkin RK, Kroh EM, Fritz BR, Wyman SK, Pogosova-Agadjanyan EL, Peterson A, Noteboom J, O'Briant KC, Allen A, Lin DW, Urban N, Drescher CW, Knudsen BS, Stirewalt DL, Gentleman R, Vessella RL, Nelson PS, Martin DB, Tewari M. Circulating microRNAs as stable blood-based markers for cancer detection. Proc Natl Acad Sci U S A. 2008 Jul 29; 105(30):10513-8. PMID: 18663219; PMCID: PMC2492472.
      Citations:    
    171. Wright JL, Lin DW, Porter MP. The association between extent of lymphadenectomy and survival among patients with lymph node metastases undergoing radical cystectomy. Cancer. 2008 Jun; 112(11):2401-8. PMID: 18383515.
      Citations:    
    172. Montgomery B, Lavori P, Garzotto M, Lee K, Brophy M, Thaneemit-Chen S, Kelly W, Basler J, Ringer R, Yu W, Whittemore A, Lin DW. Veterans Affairs Cooperative Studies Program study 553: Chemotherapy after prostatectomy, a phase III randomized study of prostatectomy versus prostatectomy with adjuvant docetaxel for patients with high-risk, localized prostate cancer. Urology. 2008 Sep; 72(3):474-80. PMID: 18407333.
      Citations:    
    173. Sim HG, Telesca D, Culp SH, Ellis WJ, Lange PH, True LD, Lin DW. Tertiary Gleason pattern 5 in Gleason 7 prostate cancer predicts pathological stage and biochemical recurrence. J Urol. 2008 May; 179(5):1775-9. PMID: 18343432.
      Citations:    
    174. Lin DW. Editorial comment on: marked gene transcript level alterations occur early during radical prostatectomy. Eur Urol. 2008 Feb; 53(2):345-6. PMID: 17448595.
      Citations:    
    175. Sabichi AL, Lerner SP, Atkinson EN, Grossman HB, Caraway NP, Dinney CP, Penson DF, Matin S, Kamat A, Pisters LL, Lin DW, Katz RL, Brenner DE, Hemstreet GP, Wargo M, Bleyer A, Sanders WH, Clifford JL, Parnes HL, Lippman SM. Phase III prevention trial of fenretinide in patients with resected non-muscle-invasive bladder cancer. Clin Cancer Res. 2008 Jan 01; 14(1):224-9. PMID: 18172274.
      Citations:    
    176. McLerran D, Grizzle WE, Feng Z, Thompson IM, Bigbee WL, Cazares LH, Chan DW, Dahlgren J, Diaz J, Kagan J, Lin DW, Malik G, Oelschlager D, Partin A, Randolph TW, Sokoll L, Srivastava S, Srivastava S, Thornquist M, Troyer D, Wright GL, Zhang Z, Zhu L, Semmes OJ. SELDI-TOF MS whole serum proteomic profiling with IMAC surface does not reliably detect prostate cancer. Clin Chem. 2008 Jan; 54(1):53-60. PMID: 18024530; PMCID: PMC4332515.
      Citations:    
    177. Lin DW. Does RPLND improve outcomes in men with intermediate-risk and high-risk germ cell tumors? Nat Clin Pract Urol. 2007 Dec; 4(12):654-5. PMID: 17971805.
      Citations:    
    178. Wright JL, Black PC, Brown GA, Porter MP, Kamat AM, Dinney CP, Lin DW. Differences in survival among patients with sarcomatoid carcinoma, carcinosarcoma and urothelial carcinoma of the bladder. J Urol. 2007 Dec; 178(6):2302-6; discussion 2307. PMID: 17936803.
      Citations:    
    179. Lin DW, Neuhouser ML, Schenk JM, Coleman IM, Hawley S, Gifford D, Hung H, Knudsen BS, Nelson PS, Kristal AR. Low-fat, low-glycemic load diet and gene expression in human prostate epithelium: a feasibility study of using cDNA microarrays to assess the response to dietary intervention in target tissues. Cancer Epidemiol Biomarkers Prev. 2007 Oct; 16(10):2150-4. PMID: 17932364.
      Citations:    
    180. Gong Z, Agalliu I, Lin DW, Stanford JL, Kristal AR. Cigarette smoking and prostate cancer-specific mortality following diagnosis in middle-aged men. Cancer Causes Control. 2008 Feb; 19(1):25-31. PMID: 17906959.
      Citations:    
    181. Agalliu I, Weiss NS, Lin DW, Stanford JL. Prostate cancer mortality in relation to screening by prostate-specific antigen testing and digital rectal examination: a population-based study in middle-aged men. Cancer Causes Control. 2007 Nov; 18(9):931-7. PMID: 17641982.
      Citations:    
    182. Porter MP, Lin DW. Trends in renal cancer surgery and patient provider characteristics associated with partial nephrectomy in the United States. Urol Oncol. 2007 Jul-Aug; 25(4):298-302. PMID: 17628295.
      Citations:    
    183. Stephenson AJ, Scardino PT, Kattan MW, Pisansky TM, Slawin KM, Klein EA, Anscher MS, Michalski JM, Sandler HM, Lin DW, Forman JD, Zelefsky MJ, Kestin LL, Roehrborn CG, Catton CN, DeWeese TL, Liauw SL, Valicenti RK, Kuban DA, Pollack A. Predicting the outcome of salvage radiation therapy for recurrent prostate cancer after radical prostatectomy. J Clin Oncol. 2007 May 20; 25(15):2035-41. PMID: 17513807; PMCID: PMC2670394.
      Citations:    
    184. Mostaghel EA, Page ST, Lin DW, Fazli L, Coleman IM, True LD, Knudsen B, Hess DL, Nelson CC, Matsumoto AM, Bremner WJ, Gleave ME, Nelson PS. Intraprostatic androgens and androgen-regulated gene expression persist after testosterone suppression: therapeutic implications for castration-resistant prostate cancer. Cancer Res. 2007 May 15; 67(10):5033-41. PMID: 17510436.
      Citations:    
    185. Sim HG, Lange PH, Lin DW. Role of post-chemotherapy surgery in germ cell tumors. Urol Clin North Am. 2007 May; 34(2):199-217; abstract ix. PMID: 17484925.
      Citations:    
    186. Mostaghel EA, Montgomery RB, Lin DW. The basic biochemistry and molecular events of hormone therapy. Curr Urol Rep. 2007 May; 8(3):224-32. PMID: 17459272.
      Citations:    
    187. Gong Z, Agalliu I, Lin DW, Stanford JL, Kristal AR. Obesity is associated with increased risks of prostate cancer metastasis and death after initial cancer diagnosis in middle-aged men. Cancer. 2007 Mar 15; 109(6):1192-202. PMID: 17311344.
      Citations:    
    188. Swartz MA, Porter MP, Lin DW, Weiss NS. Incidence of primary urethral carcinoma in the United States. Urology. 2006 Dec; 68(6):1164-8. PMID: 17141838.
      Citations:    
    189. Agalliu I, Lin DW, Salinas CA, Feng Z, Stanford JL. Polymorphisms in the glutathione S-transferase M1, T1, and P1 genes and prostate cancer prognosis. Prostate. 2006 Oct 01; 66(14):1535-41. PMID: 16921513.
      Citations:    
    190. Wright JL, Porter MP, Li CI, Lange PH, Lin DW. Differences in survival among patients with urachal and nonurachal adenocarcinomas of the bladder. Cancer. 2006 Aug 15; 107(4):721-8. PMID: 16826584.
      Citations:    
    191. Page ST, Lin DW, Mostaghel EA, Hess DL, True LD, Amory JK, Nelson PS, Matsumoto AM, Bremner WJ. Persistent intraprostatic androgen concentrations after medical castration in healthy men. J Clin Endocrinol Metab. 2006 Oct; 91(10):3850-6. PMID: 16882745.
      Citations:    
    192. Walsh TJ, Grady RW, Porter MP, Lin DW, Weiss NS. Incidence of testicular germ cell cancers in U.S. children: SEER program experience 1973 to 2000. Urology. 2006 Aug; 68(2):402-5; discussion 405. PMID: 16904461.
      Citations:    
    193. Lin DW, Coleman IM, Hawley S, Huang CY, Dumpit R, Gifford D, Kezele P, Hung H, Knudsen BS, Kristal AR, Nelson PS. Influence of surgical manipulation on prostate gene expression: implications for molecular correlates of treatment effects and disease prognosis. J Clin Oncol. 2006 Aug 10; 24(23):3763-70. PMID: 16822846.
      Citations:    
    194. Wright JL, Higano CS, Lin DW. Intermittent androgen deprivation: clinical experience and practical applications. Urol Clin North Am. 2006 May; 33(2):167-79, vi. PMID: 16631455.
      Citations:    
    195. Page ST, Plymate SR, Bremner WJ, Matsumoto AM, Hess DL, Lin DW, Amory JK, Nelson PS, Wu JD. Effect of medical castration on CD4+ CD25+ T cells, CD8+ T cell IFN-gamma expression, and NK cells: a physiological role for testosterone and/or its metabolites. Am J Physiol Endocrinol Metab. 2006 May; 290(5):E856-63. PMID: 16352669.
      Citations:    
    196. Gaylis FD, Lin DW, Ignatoff JM, Amling CL, Tutrone RF, Cosgrove DJ. Prostate cancer in men using testosterone supplementation. J Urol. 2005 Aug; 174(2):534-8; discussion 538. PMID: 16006887.
      Citations:    
    197. Lange PH, Lin DW. Does the who and how of surgery in bladder cancer matter? J Clin Oncol. 2004 Jul 15; 22(14):2762-4. PMID: 15199088.
      Citations:    
    198. Lin DW, Nelson PS. The role of cyclooxygenase-2 inhibition for the prevention and treatment of prostate carcinoma. Clin Prostate Cancer. 2003 Sep; 2(2):119-26. PMID: 15040874.
      Citations:    
    199. Lin DW, Herr HW, Dalbagni G. Value of urethral wash cytology in the retained male urethra after radical cystoprostatectomy. J Urol. 2003 Mar; 169(3):961-3. PMID: 12576822.
      Citations:    
    Lin's Networks
    Click the
    Explore
    buttons for more information and interactive visualizations!
    Concepts (467)
    Explore
    _
    Co-Authors (23)
    Explore
    _
    Similar People (60)
    Explore
    _
    Same Department Expand Description
    Explore
    _